SeaStar Medical Holding Co. (NASDAQ:ICU) Short Interest Update

SeaStar Medical Holding Co. (NASDAQ:ICU) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,590,000 shares, a growth of 10.8% from the March 15th total of 3,240,000 shares. Based on an average trading volume of 6,010,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 6.8% of the shares of the stock are sold short.

SeaStar Medical Price Performance

Shares of SeaStar Medical stock opened at $0.72 on Monday. The business has a 50 day simple moving average of $0.83 and a two-hundred day simple moving average of $0.68. SeaStar Medical has a 12 month low of $0.16 and a 12 month high of $2.50.

Hedge Funds Weigh In On SeaStar Medical

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. acquired a new stake in shares of SeaStar Medical in the fourth quarter valued at approximately $116,000. Hudson Bay Capital Management LP increased its holdings in shares of SeaStar Medical by 38.8% in the second quarter. Hudson Bay Capital Management LP now owns 346,972 shares of the company’s stock valued at $178,000 after purchasing an additional 96,972 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of SeaStar Medical in the second quarter valued at approximately $29,000. Kestra Advisory Services LLC increased its holdings in shares of SeaStar Medical by 181.5% in the fourth quarter. Kestra Advisory Services LLC now owns 81,500 shares of the company’s stock valued at $36,000 after purchasing an additional 52,550 shares during the last quarter. Finally, Geode Capital Management LLC acquired a new stake in shares of SeaStar Medical in the fourth quarter valued at approximately $63,000. Institutional investors and hedge funds own 1.69% of the company’s stock.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.